Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 21,472 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: hu14.18-IL2 fusion protein; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 54
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more

Conditions: Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Interventions: [11C]acetate; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Generalized Anxiety Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 40
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more

Conditions: Acute Ischemic Stroke From Large Vessel Occlusion
Interventions: ANA Funnel Catheter, Control; Device
Lead sponsor: Anaconda Biomed S.L.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Jacksonville, Florida • Atlanta, Georgia • Park Ridge, Illinois + 8 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 48,262 participants
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer (Diagnosis), Anal Cancer, Sexual Dysfunction Female
Interventions: Mind-Body Group Intervention, Enhanced Usual Care Control (EUCC); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 11
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure, Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency
Interventions: TricValve System, Optimal medical therapy; Device · Drug
Lead sponsor: P+F Products + Features USA Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 29 more

Conditions: Chronic Diseases, Multiple
Interventions: Intervention Group; Behavioral
Lead sponsor: Health and Healing Research Education and Service, Inc.; Other
Eligibility: 60 Years and older
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypoparathyroidism
Interventions: NPSP558; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 14
States / cities: Lakewood, California • Jacksonville, Florida • Chicago, Illinois + 11 more

Conditions: Migraine With Aura, Migraine Without Aura
Interventions: Dronabinol MDI; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 29
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more

Conditions: HIV I Infection
Interventions: VIR-1388, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: Melanoma (Skin)
Interventions: boron neutron capture therapy; Radiation
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more

Conditions: Aortic Valve Stenosis
Interventions: TAVR with CENTERA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more

Conditions: Non-infectious Anterior Uveitis, Uveitic Glaucoma
Interventions: TRS01, FDA approved steroid eye drop (masked); Drug
Lead sponsor: Tarsier Pharma; Industry
Eligibility: 0 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions: NERATINIB, FULVESTRANT; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Interventions: LNCB74; Drug
Lead sponsor: LigaChem Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Newport Beach, California • Edgewood, Kentucky • Boston, Massachusetts + 12 more

Conditions: Hypotensive Anesthesia, Orthognathic Surgery
Interventions: Dexmedetomidine, Nicardipine, Labetalol; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Zonisamide CR and Bupropion SR, Placebo; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 15
States / cities: Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Congestive Heart Failure, Left Ventricular (LV) Systolic Dysfunction
Interventions: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT); Device
Lead sponsor: CardioKinetix, Inc; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 53 more

Conditions: Leukemia
Interventions: Quizartinib, Placebo, Chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 52
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Atypical Ductal Hyperplasia
Interventions: Contrast enhanced mammography; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 30 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-traumatic Stress Disorder, Moral Injury, Traumatic Loss
Interventions: Adaptive Disclosure for Moral Injury and Loss, Present Centered Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • Boston, Massachusetts + 2 more

Search by objective public record fields.

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Feasibility of [11C]Acetate-PET in LAM and TSC

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

Healthy Eating for Successful Living in Older Adults Program (HE) Study

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Boron Neutron Capture Therapy in Treating Patients With Melanoma

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis

TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Fulvestrant + Neratinib In Breast Cancer

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Hypotensive Anesthesia for Orthognathic Surgery

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia

Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure